产品编号 :
Cas No. :
包装规格 纯度 目录价 会员专享价 库存 数量

抱歉,暂无牌价信息

晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。

基础信息

CAS No.

1826843-81-5

英文名称

-

别名

Trastuzumab Deruxtecan;Trastuzumab deruxtecan (solution);Fam-trastuzumab deruxtecan;DS-8201a|||VRN-101099|||DS 8201|||T-DXd;Enhertu;Trastuzumab deruxtecan (ADC);Trastuzumab deruxtecan (anti-ERBB2);Trastuzumab deruxtecan (DS-8201a, T-DXd)

用途

Trastuzumab deruxtecan is indicated for the treatment of unresectable or metastatic HER2-positive breast cancer in adult patients who have previously received one or more anti-HER2-based regimens; it is also approved for the treatment of HER2-low metastatic breast cancer. As the first tumor-agnostic antibody-drug conjugate (ADC), it is approved for HER2-positive solid tumors regardless of tumor origin. Additionally, it has received Breakthrough Therapy Designation (BTD) from the U.S. FDA for the treatment of unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH−) or HER2-ultra-low (IHC >0<1+) breast cancer in patients who have progressed after two lines of endocrine therapy for metastatic disease or within 6 months of first-line endocrine therapy combined with a CDK4/6 inhibitor, or within 24 months after adjuvant endocrine therapy. Trastuzumab deruxtecan demonstrates antitumor activity in HER2-positive breast cancer and gastric cancer, and exhibits a bystander killing effect against neighboring HER2-negative tumor cells.

安全信息

评论 0
我是晶智Agent,
您的化学小助手